Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Crude Oil Rises 1%; US Current Account Gap Narrows In Q3
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 20 points on Wednesday. The Dow traded up 0.06% to 37,581.68 while the NASDAQ rose 0.23% to 15,038.40. The S&P... 
Via Benzinga
Topics Stocks
US Stocks Mostly Lower; FedEx Earnings Miss Estimates
U.S. stocks traded mostly lower this morning, with the Dow Jones index falling around 75 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.21% to 37,480.08 while the... 
Via Benzinga
Topics Earnings Stocks
Why Bluebird Bio Shares Are Getting Crushed Wednesday
Bluebird Bio Inc (NASDAQ: BLUE) shares are tanking Wednesday after the company announced the pricing of a $125 million public offering of common stock< 
Via Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
Why Bluebird Bio Stock Is Tumbling Tuesday
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower Tuesday after the company announced a proposed offering. 
Via Benzinga
4 Analysts Have This to Say About bluebird bio
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
Via InvestorPlace
Why Bluebird Bio Stock Tanked After-Hours
Bluebird bio, Inc. (NASDAQ: BLUE) shares are trading lower in Monday's after-hours session after the company announced a proposed public offering of $150 million 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
An expected big win is rapidly turning into a defeat. 
Via The Motley Fool
Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%
Wall Street always think companies are high-growth potential stocks but a little circumspection is required before buying 
Via InvestorPlace
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
What's Going On With Bluebird Bio Stock?
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading higher Monday after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American... 
Via Benzinga
Cigna Calls Off Humana Merger, Joins Macy's, Snap And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow Jones futures trading almost flat on Monday. 
Via Benzinga
Topics Stocks
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.